Autifony and collaborators publish the results from a clinical trial of AUT00206 in patients with schizophrenia. The two peer-reviewed papers cover the results of studies conducted by Oliver Howes’s group at Kings College London and find important correlations between effects of AUT00206 on imaging biomarkers and measures of symptom improvement in a cohort of patients with schizophrenia:
Angelescu I, Kaar SJ, Marques TR, et al. The effect of AUT00206, a Kv3 potassium channel modulator, on dopamine synthesis capacity and the reliability of [18F]-FDOPA imaging in schizophrenia. Journal of Psychopharmacology. 2022;36(9):1061-1069. doi:10.1177/02698811221122031
Kaar SJ, Angelescu I, Nour MM, Marques TR, Sharman A, Sajjala A, Hutchison J, McGuire P, Large C, Howes OD. The effects of AUT00206, a novel Kv3.1/3.2 potassium channel modulator, on task-based reward system activation: a test of mechanism in schizophrenia. Psychopharmacology (Berl). 2022 Oct;239(10):3313-3323. doi: 10.1007/s00213-022-06216-3. Epub 2022 Sep 12. PMID: 36094619; PMCID: PMC9481488.